CD274 and lung carcinoma: Although TMB is also a promising immune biomarker for the efficacy estimate of ICI immunotherapy, the appropriate use of PD-1/PD-L1 ICIs in lung cancer is primarily determined by using levels of PD-L1 TPS to date.